London, UK-headquartered pharmaceutical giant AstraZeneca (AZ) has acknowledged that its Covid vaccine may cause blood clot-related side effects in "very rare cases", but according to court documents being cited in UK media The reason for this is unknown.
'The Daily Telegraph' reports that in a legal document submitted to the High Court in London in February for a group action by 51 claimants, A acknowledged that the vaccine developed with the University of Oxford to protect against COVID-19 The vaccine can cause thrombosis. "Very rare cases" with thrombocytopenia syndrome (TTS). The AZ Vaxjavaria vaccine, also manufactured by Seru Institute of India (SII), was known as Covishield in India.
“It is thought that the AZ vaccine may, in very rare cases, cause TTS.The causal mechanism is not known. Additionally, TTS can occur even in the absence of the TZD vaccine (or any vaccine). Causation in any individual case will matter for expert evidence,” the newspaper quoted the legal document as saying.
Lawyers acting on behalf of the claimants say they or their loved ones who received the AZ vaccine suffered TTS – a rare syndrome characterized by the presence of thrombosis or blood clots and thrombocytopenia or insufficiency of platelets. Is.
The consequences of TTS are potentially life-threatening, including stroke, brain damage, heart attack, pulmonary embolism, and amputation.Acting on behalf of 12 of 5 claimants in a group action being represented by law firm Leigh Day for damages under section 2 of the UK Consumer Protection Act 1987 against AstraZeneca UK Ltd in relation to injuries suffered as a result of the vaccine Have been. The loved one who died.
“Everyone in the group has death certificates or medical evidence that confirms the vaccine caused the deaths and injuries,” said Sarah Moore, partner at Leigh Day.
“It took a year for AstraZeneca to formally admit that their vaccine caused this harm, even though this fact had been widely accepted by the clinical community since late 2021. In that context, regrettably, it seems that AZ, the government and their lawyers are “looking to play strategic games and rack up legal fees rather than taking seriously the devastating impact the vaccine is having on the lives of our clients,” he said. Are more curious.,
The Claimants' case is that the safety of the AZ vaccine fell below the level of protection that individuals were generally entitled to expect. AZ has strongly denied the claims.
“Our sympathies go out to those who have lost loved ones or reported health issues. “Patient safety is our top priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines,” AstraZeneca said in a statement.
“Based on evidence in clinical trials and real-world data, the AstraZeneca-Oxford vaccine has consistently been shown to have an acceptable safety profile and regulators around the world consistently say the benefits of vaccination outweigh the extremely rare potential side effects .impact,” it noted.
The British-Swedish multinational says product information related to the vaccine was updated in April 2021, with UK regulatory approval, to include "the possibility that the AstraZeneca-Oxford vaccine is capable, in very rare cases, of , to be a trigger" for TTS, indicating that court documents reference this aspect rather than something new.
“It is absolutely appalling that only now is AstraZeneca admitting serious harm from its COVID vaccine. Dr Aseem Malhotra, a British Indian cardiologist who has been a Voca campaigner, said that certainly, they would have known about it from the beginning and hence there would have been serious question marks over whether it had been given to a single person in the first place. Should have gone. to the point.
The World Health Organization (WHO) has described the vaccine as "safe and effective for all persons aged 18 and over", with legal action due to adverse effects being "very rare".The claimants in the UK have provided "statements of claim" in relation to the two cases and AZ has provided its disputed liability defence. The parties have requested that the cases be managed together, and I expect a case management hearing to take place in the London High Court later this year.
SII has been contacted for comment.
'The Daily Telegraph' reports that in a legal document submitted to the High Court in London in February for a group action by 51 claimants, A acknowledged that the vaccine developed with the University of Oxford to protect against COVID-19 The vaccine can cause thrombosis. "Very rare cases" with thrombocytopenia syndrome (TTS). The AZ Vaxjavaria vaccine, also manufactured by Seru Institute of India (SII), was known as Covishield in India.
“It is thought that the AZ vaccine may, in very rare cases, cause TTS.The causal mechanism is not known. Additionally, TTS can occur even in the absence of the TZD vaccine (or any vaccine). Causation in any individual case will matter for expert evidence,” the newspaper quoted the legal document as saying.
Lawyers acting on behalf of the claimants say they or their loved ones who received the AZ vaccine suffered TTS – a rare syndrome characterized by the presence of thrombosis or blood clots and thrombocytopenia or insufficiency of platelets. Is.
The consequences of TTS are potentially life-threatening, including stroke, brain damage, heart attack, pulmonary embolism, and amputation.Acting on behalf of 12 of 5 claimants in a group action being represented by law firm Leigh Day for damages under section 2 of the UK Consumer Protection Act 1987 against AstraZeneca UK Ltd in relation to injuries suffered as a result of the vaccine Have been. The loved one who died.
“Everyone in the group has death certificates or medical evidence that confirms the vaccine caused the deaths and injuries,” said Sarah Moore, partner at Leigh Day.
“It took a year for AstraZeneca to formally admit that their vaccine caused this harm, even though this fact had been widely accepted by the clinical community since late 2021. In that context, regrettably, it seems that AZ, the government and their lawyers are “looking to play strategic games and rack up legal fees rather than taking seriously the devastating impact the vaccine is having on the lives of our clients,” he said. Are more curious.,
The Claimants' case is that the safety of the AZ vaccine fell below the level of protection that individuals were generally entitled to expect. AZ has strongly denied the claims.
“Our sympathies go out to those who have lost loved ones or reported health issues. “Patient safety is our top priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines,” AstraZeneca said in a statement.
“Based on evidence in clinical trials and real-world data, the AstraZeneca-Oxford vaccine has consistently been shown to have an acceptable safety profile and regulators around the world consistently say the benefits of vaccination outweigh the extremely rare potential side effects .impact,” it noted.
The British-Swedish multinational says product information related to the vaccine was updated in April 2021, with UK regulatory approval, to include "the possibility that the AstraZeneca-Oxford vaccine is capable, in very rare cases, of , to be a trigger" for TTS, indicating that court documents reference this aspect rather than something new.
“It is absolutely appalling that only now is AstraZeneca admitting serious harm from its COVID vaccine. Dr Aseem Malhotra, a British Indian cardiologist who has been a Voca campaigner, said that certainly, they would have known about it from the beginning and hence there would have been serious question marks over whether it had been given to a single person in the first place. Should have gone. to the point.
The World Health Organization (WHO) has described the vaccine as "safe and effective for all persons aged 18 and over", with legal action due to adverse effects being "very rare".The claimants in the UK have provided "statements of claim" in relation to the two cases and AZ has provided its disputed liability defence. The parties have requested that the cases be managed together, and I expect a case management hearing to take place in the London High Court later this year.
SII has been contacted for comment.
